External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology
- PMID: 21944989
- DOI: 10.1016/j.juro.2011.07.034
External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology
Abstract
Purpose: The Leibovich prognosis score was developed as a prognostic tool for metastatic disease after radical nephrectomy for clear cell renal cell carcinoma using pathology review. However, this scoring system has never been externally validated. We externally validated its prognostic accuracy using routine pathology reports.
Materials and methods: We retrospectively evaluated data from the routine pathology records of 1,754 consecutive patients with nonmetastatic clear cell renal cell carcinoma operated on between 1984 and 2006 at a single tertiary academic center. Clear cell renal cell carcinoma cases were categorized as 0 to 11 by the Leibovich prognosis score and further stratified into low, intermediate and high risk groups. Metastasis-free survival was assessed using the Kaplan-Meier method. To evaluate the prognostic impact a multivariate Cox regression model was used and prognostic accuracy was determined using Harrell's concordance index.
Results: Median followup was 82 months (IQR 39-142). Metastasis developed in 375 of the 1,754 patients (21.4%). The 10-year metastasis-free survival rate for Leibovich scores in our study ranged from 95% for scores of 0 and 1 to 12% for scores of 8 or greater. Pathological T stage, N stage, low tumor grade, large tumor diameter and histological tumor necrosis were independent predictors of metastasis-free survival (p <0.001). Harrell's concordance index was 0.778.
Conclusions: Risk prediction by the Leibovich prognosis score using routine pathological results was comparable to that of the original data based on pathology review. Our data support using the Leibovich prognosis score in clinical practice for followup decisions and patient selection for adjuvant treatment trials.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Editorial comment.J Urol. 2011 Nov;186(5):1777-8. doi: 10.1016/j.juro.2011.07.127. Epub 2011 Sep 25. J Urol. 2011. PMID: 21944987 No abstract available.
Similar articles
-
External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.Eur Urol. 2010 Jan;57(1):102-9. doi: 10.1016/j.eururo.2008.11.033. Epub 2008 Nov 28. Eur Urol. 2010. PMID: 19062157
-
Prognostic value of the Leibovich prognosis score supplemented by vascular invasion for clear cell renal cell carcinoma.J Urol. 2012 Mar;187(3):834-9. doi: 10.1016/j.juro.2011.10.155. Epub 2012 Jan 15. J Urol. 2012. PMID: 22245331
-
Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma.Urology. 2010 Jun;75(6):1365-1370; 1370.e1-3. doi: 10.1016/j.urology.2009.07.1289. Urology. 2010. PMID: 20022084
-
Survival after renal cell carcinoma metastasis to the thyroid: single center experience and systematic review of the literature.Thyroid. 2015 Mar;25(3):314-24. doi: 10.1089/thy.2014.0498. Epub 2015 Jan 14. Thyroid. 2015. PMID: 25491306 Review.
-
Mathematical models for prognostic prediction in patients with renal cell carcinoma.Urol Int. 2008;80(2):113-23. doi: 10.1159/000112599. Epub 2008 Mar 19. Urol Int. 2008. PMID: 18362478 Review.
Cited by
-
High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients.Br J Cancer. 2013 Sep 3;109(5):1123-9. doi: 10.1038/bjc.2013.443. Epub 2013 Aug 6. Br J Cancer. 2013. PMID: 23922109 Free PMC article.
-
UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time.Urology. 2020 Feb;136:162-168. doi: 10.1016/j.urology.2019.09.044. Epub 2019 Nov 6. Urology. 2020. PMID: 31705948 Free PMC article.
-
Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence.Am J Pathol. 2018 Nov;188(11):2487-2496. doi: 10.1016/j.ajpath.2018.07.026. Epub 2018 Sep 8. Am J Pathol. 2018. PMID: 30201497 Free PMC article.
-
A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma.Sci Rep. 2021 Apr 21;11(1):8650. doi: 10.1038/s41598-021-88177-9. Sci Rep. 2021. PMID: 33883645 Free PMC article.
-
Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date.Cancer Manag Res. 2020 Jun 23;12:4871-4881. doi: 10.2147/CMAR.S202017. eCollection 2020. Cancer Manag Res. 2020. PMID: 32606975 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical